Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the

  Echo Therapeutics Announces Closing of Public Offering of Common Stock And
          Full Exercise of Over-Allotment Option by the Underwriter

PR Newswire

PHILADELPHIA, June 19, 2013

PHILADELPHIA, June 19, 2013 /PRNewswire/ --Echo Therapeutics, Inc. (Nasdaq:
ECTE), a company developing its needle-free Symphony^® CGM System as a
non-invasive, wireless continuous glucose monitoring system, today announced
the closing of a previously announced underwritten public offering of
4,025,000 shares of its common stock and the full exercise of the
over-allotment option to purchase 603,750 additional shares, offered at a
price to the public of $2.70 per share.The total gross proceeds to Echo from
this offering are approximately $12,500,000 before deducting the underwriting
discount and other estimated offering expenses payable by Echo.

(Logo: http://photos.prnewswire.com/prnh/20120801/NE50071LOGO )

Aegis Capital Corp. acted as the sole book-running manager for the offering.

The offering is being made pursuant to a shelf registration statement that
Echo previously filed with the Securities and Exchange Commission (the "SEC")
and which is effective. A final prospectus supplement and accompanying base
prospectus relating to the offering has been filed with the SEC and is
available on the SEC's website located at www.sec.gov. Electronic copies of
the final prospectus supplement may also be obtained by contacting Aegis
Capital Corp., Prospectus Department, 810 Seventh Avenue, 18^th Floor, New
York, NY, 10019, telephone: (212) 813-1010 or email: prospectus@aegiscap.com.

This press release does not constitute an offer to sell, or the solicitation
of an offer to buy, these securities, nor will there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale is not permitted.

About Echo Therapeutics

Echo Therapeutics is developing the Symphony CGM System as a non-invasive,
wireless continuous glucose monitoring system. Our target is patients who
could benefit from glucose monitoring in the hospital setting, including
critical care. Significant opportunity also exists for patients with diabetes
to use Symphony in the outpatient setting. Echo is also developing its
needle-free skin preparation component of Symphony, the Prelude^® SkinPrep
System, as a platform technology to enhance drug delivery of topical
pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may
constitute forward-looking statements that are based on current expectations
and are subject to risks and uncertainties that could cause actual future
results to differ materially from those expressed or implied by such
statements. Those risks and uncertainties include, but are not limited to,
risks related to regulatory approvals and the success of Echo's ongoing
studies, including the safety and efficacy of Echo's Symphony CGM System, the
failure of future development and preliminary marketing efforts related to
Echo's Symphony CGM System, Echo's ability to secure additional commercial
partnering arrangements, risks and uncertainties relating to Echo's and its
partners' ability to develop, market and sell the Symphony CGM System, the
availability of substantial additional equity or debt capital to support its
research, development and product commercialization activities, and the
success of its research, development, regulatory approval, marketing and
distribution plans and strategies, including those plans and strategies
related to its Symphony CGM System. These and other risks and uncertainties
are identified and described in more detail in Echo's filings with the
Securities and Exchange Commission, including, without limitation, its Annual
Report on Form 10-K for the year ended December 31, 2012, its Quarterly
Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no
obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H.
Olimpio
Director, Investor Relations and Corporate Communications
(215)
717-4104

Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at http://www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx

SOURCE Echo Therapeutics, Inc.

Website: http://www.echotx.com